Statement on the passing of José Baselga

Report this content

AstraZeneca today issued the following statement from Pascal Soriot, Chief Executive Officer.

“We are deeply saddened by the news that José Baselga, Executive Vice President Oncology R&D, and member of our Senior Executive Team, has passed away.

An outstanding scientific leader, José leaves a lasting legacy in the scientific community and here at AstraZeneca. He set our Oncology R&D function on a remarkable trajectory, and his visionary leadership, deep scientific expertise and strategic insight have delivered so many achievements that we can all be proud of and that will benefit patients’ lives in the years to come. 

José championed our transformative collaborations with Daiichi-Sankyo in relation to the clinical development of Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan, two medicines which have demonstrated great potential to benefit cancer patients. He led a team to accelerate other exciting new science in antibody-drug conjugates, cell therapy, epigenetics, as well as new cancer treatments. He also championed the use of real-world evidence and digital tools to transform the way we design and implement clinical trials.

José built a world-class Oncology R&D team who will miss him dearly, just as all his colleagues will throughout our entire Company.

José was more than a colleague to me. He was a friend, and someone I immensely respected and cherished. I will enormously miss having him alongside me, and I will continue to be inspired by his work and vision.

My heart goes out to his wife Silvia and his four children.”


AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.


For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Christina Malmberg Hägerstrand
Presschef AstraZeneca AB och Norden Baltikum
+ 46 8 552 53 106